MedTrace Logo

A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection

NCT00979667 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2011-04-11

No results posted yet for this study

Summary

To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.

Conditions

Interventions

DRUG

Oseltamivir

75 mg twice daily for 5 days

DRUG

Zanamivir

10 mg twice daily for 5 days

DRUG

Placebo of Oseltamivir

twice daily for 5 days

Sponsors & Collaborators

  • Food and Health Bureau, Hong Kong

    collaborator OTHER_GOV

  • Hospital Authority

    collaborator AMBIG

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Augustine T. LAM, MBBS · Prince of Wales Hospital, Shatin, Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-08-31
Completion
2010-10-31

Countries

  • China
  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00979667 on ClinicalTrials.gov